Pfizer 2011 Annual Report Download - page 27

Download and view the complete annual report

Please find page 27 of the 2011 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 117

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117

Financial Review
Pfizer Inc. and Subsidiary Companies
and focusing on areas with the highest potential to deliver value in the near term and over time. To that end, our research primarily
focuses on five high-priority areas that have a mix of small and large molecules –– immunology and inflammation; oncology;
cardiovascular, metabolic and endocrine diseases; neuroscience and pain; and vaccines.
Our development pipeline, which is updated quarterly, can be found at www.pfizer.com/pipeline. It includes an overview of our
research and a list of compounds in development with targeted indication, phase of development and, for late-stage programs,
mechanism of action. The information currently in our development pipeline is accurate as of February 28, 2012.
Below are significant regulatory actions by, and filings pending with, the FDA and regulatory authorities in the EU and Japan, as well
as new drug candidates and additional indications in late-stage development:
Recent FDA approvals:
PRODUCT INDICATION DATE APPROVED
INLYTA (Axitinib) Treatment of advanced renal cell carcinoma after failure of one prior systemic
therapy
January 2012
Prevnar 13 Adult Prevention of pneumococcal pneumonia and invasive disease in adults 50 years of
age and older
December 2011
Xalkori (Crizotinib) Treatment of ALK-positive advanced non-small cell lung cancer August 2011
Oxecta––Immediate
release oxycodone
with Aversion
technology
(formerly
Acurox) (without
niacin)(a)
Management of moderate-to-severe pain where the use of an opioid analgesic is
appropriate
June 2011
Sutent Treatment of unresectable pancreatic neuroendocrine tumor May 2011
(a) In early 2011, we acquired King, which has an exclusive license from Acura Pharmaceuticals, Inc. (Acura) to sell Oxecta in the U.S., Canada and
Mexico.
Pending U.S. new drug applications (NDA) and supplemental filings:
PRODUCT INDICATION DATE FILED*
Tafamidis meglumine Treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) February 2012
Lyrica Treatment of central neuropathic pain due to spinal cord injury February 2012
Revatio Pediatric PAH January 2012
Bosutinib Treatment of previously treated chronic myelogenous leukemia January 2012
Tofacitinib Treatment of moderate-to-severe active rheumatoid arthritis December 2011
Apixaban(a) Prevention of stroke and systemic embolism in patients with atrial fibrillation November 2011
Taliglucerase alfa(b) Treatment of Gaucher disease April 2010
Genotropin(c) Replacement of human growth hormone deficiency (Mark VII multidose disposable
device)
December 2009
Celebrex(d) Chronic pain October 2009
Geodon(e) Treatment of bipolar disorder––pediatric filing December 2008
Remoxy(f) Management of moderate-to-severe pain when a continuous, around-the-clock
opioid analgesic is needed for an extended period of time
August 2008
Spiriva(g) Respimat device for chronic obstructive pulmonary disease January 2008
Zmax(h) Treatment of bacterial infections––sustained release––acute otitis media (AOM)
and sinusitis––pediatric filing
January 2007
Viviant(i) Osteoporosis treatment and prevention August 2006
Vfend(j) Treatment of fungal infections––pediatric filing August 2005
* The dates set forth in this column are the dates on which the FDA accepted our submissions.
(a) This indication for apixaban is being developed in collaboration with our alliance partner, BMS.
(b) In November 2009, we entered into a license and supply agreement with Protalix BioTherapeutics (Protalix), which provides us exclusive worldwide
rights, except in Israel, to develop and commercialize taliglucerase alfa for the treatment of Gaucher disease. In April 2010, Protalix completed a
rolling NDA with the FDA for taliglucerase alfa. Taliglucerase alfa was granted orphan drug designation in the U.S. in September 2009. In February
2011, Protalix received a “complete response” letter from the FDA for the taliglucerase alfa NDA that set forth additional requirements for approval.
On August 1, 2011, Protalix announced that it had submitted its response to the FDA letter.
26 2011 Financial Report